Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 1, 2006, Pages 51-57

  Tomas, D ^a   Kruslin B ^a   Cupic H ^a   Stanimirovic A ^a   Bosnjak B ^b   Lovricevic I ^a   Belicza, M ^a  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b PLIVA Research Institute Ltd   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PEROXIDASE; POLYCLONAL ANTIBODY; PROTEIN ANTIBODY; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; STREPTAVIDIN;

ACTINIC KERATOSIS; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; AUTOMATION; CHI SQUARE TEST; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANK SUM TEST; SKIN ATROPHY; SKIN CARCINOMA; SKIN HYPERTROPHY; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ATROPHY; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; HYPERTROPHY; IMMUNOENZYME TECHNIQUES; KERATOSIS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646010024     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01364.x     Document Type: Article

References (49)

1. Gupta AK, Cooper EA, Feldman SR, Fleischer AB Jr. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-99. National Ambulatory Medical Care Survey. Cutis 2002; 70: 8-13.
2. Holman CD, Armstrong DK, Evans PR et al. Relationship of solar keratosis and history of skin cancer to objective measures of actinic skin damage. Br J Dermatol 1984; 110: 129-138.
3. Vitasa BC, Taylor HR, Strickland PT et al. Association of non-melanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer 1990; 65: 2811-2817.
4. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000; 42: 18-22.
5. Onodera H, Nakamura S, Sugai T. Cell proliferation and P53 protein expression in cutaneous epithelial neoplasms. Am J Dermatopathol 1996; 18: 580-588.
6. Bito T, Ueda M, Ahmed NU, Nagano T, Ichihashi M. Cyclin D and retinoblastoma gene product expression in actinic keratosis and cutaneous squamous cell carcinoma in relation to p53 expression. J Cutan Pathol 1995; 22: 427-434.
7. Radfar A, Unnikrishnan I, Lee HW, DePinho RA, Rosenberg N. p19 (Arf) induces P53-dependent apoptosis during abelson virus-mediated pre-B-cell transformation. Proc Natl Acad Sci USA 1998; 95: 13194-13199.
8. de Gruijl FR. Skin cancer and solar UV radiation. Eur J Cancer 1999; 35: 2003-2009.
9. Ortonne JP. From actinic keratosis to squamous cell carcinoma. Br J Dermatol 2002; 146: 20-23.
10. Hollstein M, Halnaut M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 1998; 77: 81-125.
11. Basset-Seguin N, Moles JP, Mils V, Dereure O, Guilhou JJ. Tp53 tumor suppressor gene and skin carcinogenesis. J Invest Dermatol 1994; 103: 1025-1065.
12. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
13. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimers in vivo with conversed homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
14. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
15. Raisova M, Hossini AM, Eberle J et al. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. J Invest Dermatol 2001; 117: 330-336.
16. Sermadiras S, Dumas M, Joly-Berville R et al. Expression of Bcl-2 and Bax in cultured normal human keratinocytes and melanocytes: Relationship to differentiation and melanogenesis. Br J Dermatol 1997; 137: 883-889.
17. Cho SH, Delehedde M, Rodriguez-Villanueva J, Brisbay S, McDonnel TJ. Bax gene disruption alters the epidermal response to ultraviolet irradiation and in vivo induced skin carcinogenesis. Int J Mol Med 2001; 7: 235-241.
18. Adhami VM, Aziz MH, Mukhtar H, Ahmad N. Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. Clin Cancer Res 2003; 9: 3176-3182.
19. Pinkus H. Keratosis senilis: A biologic concept of its pathogenesis and diagnosis based on the study of normal epidermis and 1730 seborrheic and senile keratoses. Am J Clin Pathol 1958; 29: 193-207.
20. Kuflik AS, Schwartz RA. Actinic keratosis and squamous cell carcinoma. Am Fam Physician 1994; 49: 817-820.
21. Kwa RE, Campana K, Moy RL. Biology of cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992; 26: 1-26.
22. Person JR. An actinic keratosis is neither malignant nor premalignant: it is an initiated tumor. J Am Acad Dermatol 2003; 48: 637-638.
23. Ackerman AB. Solar keratosis is squamous cell carcinoma. Arch Dermatol 2003; 139: 1216-1217.
24. Lober BA, Lober CW. Actinic keratosis is squamous cell carcinoma. South Med J 2000; 93: 650-655.
25. Guenthner ST, Hurwitz RM, Buckel LJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation. J Am Acad Dermatol 1999; 41: 443-448.
26. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutational spectra studies of tumor suppressor genes. Cancer Res 1998; 58: 4023-4037.
27. Helander SD, Peters MS, Pittelkow MR. Expression of p53 protein in benign and malignant epidermal pathologic condition. J Am Acad Dermatol 1993; 29: 741-748.
28. Jonason AS, Kunala S, Price GJ et al. Frequent clones of p53-mutated keratinocytes in normal skin. Proc Natl Acad Sci USA 1996; 93: 14025-14029.
29. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-207.
30. Ren ZP, Hedrum A, Ponten F et al. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes. Oncogene 1996; 12: 765-733.
31. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-776.
32. Inohara S, Kitagawa K, Kitano Y. Coexpression of p21 waf1/Cip1 and p53 in sun-exposed normal epidermis. Br J Dermatol 1996; 136: 717-720.
33. Rees J. Genetic alterations in non-melanoma skin cancer. J Invest Dermatol 1994; 103: 747-750.
34. Crosthwaite N, Teale D, Franklin C, Foster GA, Stringer BM. p53 protein expression in malignant, pre-malignant and nonmalignant lesions of the lip. J Clin Pathol 1996; 49: 648-653.
35. Sim CS, Slater S, McKee PH. Mutant p53 expression in solar keratosis: An immunohistochemical study. J Cutan Pathol 1992; 19: 302-308.
36. Stanimirović A, Čupić H, Bošnjak B, Krušlin B, Belicza M. Expression of p53, bcl-2 and growth hormone receptor in actinic keratosis, hypertrophic type. Arch Dermatol Res 2003; 295: 102-108.
37. Stanimirović A, Čupić H, Bošnjak B et al. Expression of p53, bcl-2 and growth hormone receptor in atrophic type of actinic keratosis. J Dermatol Sci 2004; 34: 49-53.
38. Einspahr JG, Alberts DS, Warneke JA et al. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia 1999; 1: 468-475.
39. Shimizu T, Oga A, Murakami T, Muto M. Overexpression of P53 protein associated with proliferative activity and histological degree of malignancy in solar keratosis. Dermatology 1999; 199: 113-118.
40. McDonnell TJ, Beham A, Sarkiss M, Andersen MM, Lo P. Importance of the bcl-2 family in cell death regulation. Experientia 1996; 52: 1008-1017.
41. Delehedde M, Cho SH, Sarkiss M et al. Altered expression of bcl-2 family member proteins in non-melanoma skin cancer. Cancer 1999; 85: 1514-1522.
42. Nakagawa K, Yamamura K, Maeda S, Ichihashi M. Bcl-2 expression in epidermal keratinocytic diseases. Cancer 1994; 74: 1720-1724.
43. Morales-Ducret CR, van de Rijn M, LeBrun DP, Smoller BR. Bcl-2 expression in primary malignancies of the skin. Arch Dermatol 1995; 131: 909-912.
44. Mills AE. Solar keratosis can be distinguished from superficial basal cell carcinoma by expression of bcl-2. Am J Dermatopathol 1997; 19: 443-445.
45. Tucci MG, Offidani A, Lucarini G et al. Advances in the understanding of malignant transformation of keratinocytes: An immunohistochemical study. J Eur Acad Dermatol Venereol 1998; 10: 118-124.
46. Feinmesser M, Tsabari C, Fichman S et al. Differential expression of proliferation- and apoptosis-related markers in lentigo maligna and solar keratosis keratinocytes. Am J Dermatopathol 2003; 25: 300-307.
47. Tomkova H, Fujimoto W, Arata J. Expression of the bcl-2 homologue bax in normal human skin, psoriasis vulgaris and non-melanoma skin cancers. Eur J Dermatol 1998; 8: 256-260.
48. Wrone-Smith T, Bergstrom J, Quevedo ME et al. Differential expression of cell survival and cell cycle regulatory proteins in cutaneous squamoproliferative lesions. J Derm Sci 1999; 19: 53-67.
49. Takahashi H, Aoki N, Nakamura S et al. Cornified cell envelope formation is distinct from apoptosis in epidermal keratinocytes. J Dermatol Sci 2000; 23: 161-169.